CUPERTINO, Calif., Jan. 3, 2019 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) invites interested parties to listen to
a corporate update conference call that will be broadcast live over
the internet on Monday, January 7,
2019 at 8:00 am Eastern Time
(5:00 am Pacific Time).
A live audio webcast of the presentation will be available by
accessing DURECT's homepage at www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury such as Alcoholic Hepatitis (AH),
hepatic and renal diseases such as nonalcoholic steatohepatitis
(NASH) and Primary Sclerosing Cholangitis (PSC), and inflammatory
skin conditions such as psoriasis and atopic dermatitis.
DURECT's advanced oral and injectable delivery technologies are
designed to enable new indications and enhanced attributes for
small-molecule and biologic drugs. Late stage product
candidates in this category include POSIMIR®
(bupivacaine extended release solution), an investigational
locally-acting, non-opioid analgesic intended to provide up to 3
days of continuous pain relief after surgery, and
ORADUR®-Methylphenidate ER Capsules, approved in
Taiwan as Methydur Sustained
Release Capsules, where it is indicated for the treatment of
attention deficit hyperactivity disorder (ADHD). In addition,
for the assignment of certain patent rights, DURECT will receive
single digit sales-based earn-out payments from U.S. net sales of
Indivior's PERSERIS™ (risperidone) drug for
schizophrenia, which was approved in July 2018. For more
information, please visit www.durect.com.
NOTE: ORADUR®, POSIMIR® and
SABER® are trademarks of DURECT Corporation.
Other referenced trademarks belong to their respective
owners. DUR-928 and POSIMIR are drug candidates under
development and have not been approved for commercialization by the
U.S. Food and Drug Administration or other health authorities.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential
benefits and uses of DURECT's drug candidates, including the
potential use of DUR-928 to treat Alcoholic Hepatitis, hepatic and
renal diseases such as nonalcoholic steatohepatitis (NASH) and
Primary Sclerosing Cholangitis (PSC), and inflammatory skin
conditions such as psoriasis and atopic dermatitis, the potential
use of POSIMIR to treat post-surgical pain, the potential use of
ORADUR-Methylphenidate to treat ADHD, and the potential for
sales-based earn-out payments from the sale of Indivior's PERSERIS
to treat schizophrenia are forward-looking statements involving
risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential
risks and uncertainties include, but are not limited to, the
possibility that studies of DUR-928 will not replicate results from
earlier preclinical or clinical trials, the risks that Indivior
will not launch PERSERIS commercially or that it will not obtain
market acceptance and meaningful sales, as well as possible adverse
events associated with the use of PERSERIS, POSIMIR,
ORADUR-Methylphenidate and DUR-928, and delays and costs due to
additional work or other requirements imposed by regulatory
agencies for continued development, approval or sale of POSIMIR,
ORADUR-Methylphenidate and DUR-928. Further information
regarding risks related to DUR-928, POSIMIR and
ORADUR-Methylphenidate and other risks related to DURECT is
included in DURECT's Form 10-Q filed on November 8, 2018 under the heading "Risk
Factors."
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-announces-investor-call-to-provide-corporate-update-300772627.html
SOURCE DURECT Corporation